{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:53:44Z","timestamp":1787550824437,"version":"build-2736575974"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000953","name":"Alliance for Cancer Gene Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000953","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011098","name":"SU | Stanford Bio-X","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010865","name":"SU | Stanford Engineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["DP2AG067666"],"award-info":[{"award-number":["DP2AG067666"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["COV-440388"],"award-info":[{"award-number":["COV-440388"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-026-01704-9","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:04:15Z","timestamp":1781255055000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rewiring oncogenic signalling to precision ablation of metastatic cancer"],"prefix":"10.1038","author":[{"given":"Xinzhi","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3205-9137","authenticated-orcid":false,"given":"Elizabeth","family":"Palafox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3390-2382","authenticated-orcid":false,"given":"Cynthia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-1338","authenticated-orcid":false,"given":"Kevin T.","family":"Beier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chil-Yong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0492-1961","authenticated-orcid":false,"given":"Michael Z.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"1704_CR1","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1002\/cncr.33587","volume":"127","author":"F Bray","year":"2021","unstructured":"Bray, F., Laversanne, M., Weiderpass, E. & Soerjomataram, I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 127, 3029\u20133030 (2021).","journal-title":"Cancer"},{"key":"1704_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A. & Fares, Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct. Target. Ther. 5, 28 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1704_CR3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","volume":"8","author":"Global Burden of Disease Cancer, C.","year":"2022","unstructured":"Global Burden of Disease Cancer, C. et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 8, 420\u2013444 (2022).","journal-title":"JAMA Oncol."},{"key":"1704_CR4","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1080\/15384047.2018.1456599","volume":"19","author":"L Jin","year":"2018","unstructured":"Jin, L. et al. Breast cancer lung metastasis: molecular biology and therapeutic implications. Cancer Biol. Ther. 19, 858\u2013868 (2018).","journal-title":"Cancer Biol. Ther."},{"key":"1704_CR5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/emmm.201100176","volume":"3","author":"D Torti","year":"2011","unstructured":"Torti, D. & Trusolino, L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol. Med. 3, 623\u2013636 (2011).","journal-title":"EMBO Mol. Med."},{"key":"1704_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon, D. J. et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707\u2013712 (1989).","journal-title":"Science"},{"key":"1704_CR7","doi-asserted-by":"publisher","first-page":"114371","DOI":"10.18632\/oncotarget.22825","volume":"8","author":"R Mishra","year":"2017","unstructured":"Mishra, R., Hanker, A. B. & Garrett, J. T. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 8, 114371\u2013114392 (2017).","journal-title":"Oncotarget"},{"key":"1704_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pathol.2022.11.004","volume":"55","author":"KL Talia","year":"2023","unstructured":"Talia, K. L., Banet, N. & Buza, N. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma. Pathology 55, 8\u201318 (2023).","journal-title":"Pathology"},{"key":"1704_CR9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clbc.2023.03.007","volume":"23","author":"J O\u2019Shaughnessy","year":"2023","unstructured":"O\u2019Shaughnessy, J., Gradishar, W., O\u2019Regan, R. & Gadi, V. Risk of recurrence in patients with HER2+ early-stage breast cancer: literature analysis of patient and disease characteristics. Clin Breast Cancer 23, 350\u2013362 (2023).","journal-title":"Clin Breast Cancer"},{"key":"1704_CR10","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat. Med. 30, 2208\u20132215 (2024).","journal-title":"Nat. Med."},{"key":"1704_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug. Discov. 22, 101\u2013126 (2023).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1704_CR12","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/cancers16071336","volume":"16","author":"MK Scheck","year":"2024","unstructured":"Scheck, M. K., Hofheinz, R. D. & Lorenzen, S. HER2-positive gastric cancer and antibody treatment: state of the art and future developments. Cancers 16, 1336 (2024).","journal-title":"Cancers"},{"key":"1704_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II Trial. J. Clin. Oncol. 42, 47\u201358 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1704_CR14","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/cancers15041130","volume":"15","author":"L Guidi","year":"2023","unstructured":"Guidi, L., Pellizzari, G., Tarantino, P., Valenza, C. & Curigliano, G. Resistance to antibody-drug conjugates targeting HER2 in breast cancer: molecular landscape and future challenges. Cancers 15, 1130 (2023).","journal-title":"Cancers"},{"key":"1704_CR15","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","volume":"18","author":"T Doi","year":"2017","unstructured":"Doi, T. et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 18, 1512\u20131522 (2017).","journal-title":"Lancet Oncol."},{"key":"1704_CR16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-2600(20)30455-0","volume":"9","author":"Y Shi","year":"2021","unstructured":"Shi, Y. et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir. Med. 9, 829\u2013839 (2021).","journal-title":"Lancet Respir. Med."},{"key":"1704_CR17","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.hoc.2023.05.009","volume":"37","author":"JA Wala","year":"2023","unstructured":"Wala, J. A. & Hanna, G. J. Chimeric antigen receptor T-cell therapy for solid tumors. Hematol. Oncol. Clin. North Am. 37, 1149\u20131168 (2023).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"1704_CR18","first-page":"183","volume":"12","author":"M Wen","year":"2018","unstructured":"Wen, M. et al. Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation. Biologics 12, 183\u2013190 (2018).","journal-title":"Biologics"},{"key":"1704_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00265-1","volume":"7","author":"I Schlam","year":"2021","unstructured":"Schlam, I. & Swain, S. M. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. npj Breast Cancer 7, 56 (2021).","journal-title":"npj Breast Cancer"},{"key":"1704_CR20","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.3390\/cancers14246257","volume":"14","author":"A Skorda","year":"2022","unstructured":"Skorda, A., Bay, M. L., Hautaniemi, S., Lahtinen, A. & Kallunki, T. Kinase inhibitors in the treatment of ovarian cancer: current state and future promises. Cancers 14, 6257 (2022).","journal-title":"Cancers"},{"key":"1704_CR21","first-page":"282","volume":"4","author":"P Malaguti","year":"2015","unstructured":"Malaguti, P., D\u2019Aloia, M. M. & Alimandi, M. The ErbB2 receptor in gastric cancer. the quick-change artist. Transl. Gastrointest. Cancer 4, 282\u2013293 (2015).","journal-title":"Transl. Gastrointest. Cancer"},{"key":"1704_CR22","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3389\/fonc.2019.01308","volume":"9","author":"C Arienti","year":"2019","unstructured":"Arienti, C., Pignatta, S. & Tesei, A. Epidermal growth factor receptor family and its role in gastric cancer. Front. Oncol. 9, 1308 (2019).","journal-title":"Front. Oncol."},{"key":"1704_CR23","doi-asserted-by":"publisher","first-page":"eaat6982","DOI":"10.1126\/science.aat6982","volume":"364","author":"HK Chung","year":"2019","unstructured":"Chung, H. K. et al. A compact synthetic pathway rewires cancer signaling to therapeutic effector release. Science 364, eaat6982 (2019).","journal-title":"Science"},{"key":"1704_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0014-5793(01)02117-2","volume":"490","author":"H Waterman","year":"2001","unstructured":"Waterman, H. & Yarden, Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 490, 142\u2013152 (2001).","journal-title":"FEBS Lett."},{"key":"1704_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejps.2016.11.003","volume":"97","author":"MI Titze","year":"2017","unstructured":"Titze, M. I. et al. A generic viral dynamic model to systematically characterize the interaction between oncolytic virus kinetics and tumor growth. Eur. J. Pharm. Sci. 97, 38\u201346 (2017).","journal-title":"Eur. J. Pharm. Sci."},{"key":"1704_CR26","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","volume":"78","author":"M Garbutt","year":"2004","unstructured":"Garbutt, M. et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78, 5458\u20135465 (2004).","journal-title":"J. Virol."},{"key":"1704_CR27","doi-asserted-by":"publisher","first-page":"e0162723","DOI":"10.1128\/jvi.01627-23","volume":"98","author":"EM Anderson","year":"2024","unstructured":"Anderson, E. M. & Coller, B.-A. G. Translational success of fundamental virology: a VSV-vectored Ebola vaccine. J. Virol. 98, e0162723 (2024).","journal-title":"J. Virol."},{"key":"1704_CR28","first-page":"213","volume":"330","author":"SJ Russell","year":"2009","unstructured":"Russell, S. J. & Peng, K. W. Measles virus for cancer therapy. Curr. Top. Microbiol. Immunol. 330, 213\u2013241 (2009).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1704_CR29","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.3390\/cancers15164178","volume":"15","author":"C Lovatt","year":"2023","unstructured":"Lovatt, C. & Parker, A. L. Oncolytic viruses and immune checkpoint inhibitors: the \u2018hot\u2019 new power couple. Cancers 15, 4178 (2023).","journal-title":"Cancers"},{"key":"1704_CR30","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1002\/1873-3468.13700","volume":"593","author":"G Nemerow","year":"2019","unstructured":"Nemerow, G. & Flint, J. Lessons learned from adenovirus (1970-2019). FEBS Lett. 593, 3395\u20133418 (2019).","journal-title":"FEBS Lett."},{"key":"1704_CR31","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.4161\/cbt.4.11.2137","volume":"4","author":"X Zheng","year":"2005","unstructured":"Zheng, X. et al. Adenoviral E1a expression levels affect virus-selective replication in human cancer cells. Cancer Biol. Ther. 4, 1255\u20131262 (2005).","journal-title":"Cancer Biol. Ther."},{"key":"1704_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12794-2","volume":"10","author":"H Huang","year":"2019","unstructured":"Huang, H. et al. Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy. Nat. Commun. 10, 4801 (2019).","journal-title":"Nat. Commun."},{"key":"1704_CR33","doi-asserted-by":"publisher","first-page":"752504","DOI":"10.3389\/fonc.2021.752504","volume":"11","author":"R Zhang","year":"2021","unstructured":"Zhang, R., Cui, Y., Guan, X. & Jiang, X. A recombinant human adenovirus type 5 (H101) combined with chemotherapy for advanced gastric carcinoma: a retrospective cohort study. Front. Oncol. 11, 752504 (2021).","journal-title":"Front. Oncol."},{"key":"1704_CR34","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1089\/hum.2008.047","volume":"19","author":"M Bazan-Peregrino","year":"2008","unstructured":"Bazan-Peregrino, M. et al. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum. Gene Ther. 19, 873\u2013886 (2008).","journal-title":"Hum. Gene Ther."},{"key":"1704_CR35","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.3390\/v7112905","volume":"7","author":"PH Cheng","year":"2015","unstructured":"Cheng, P. H., Wechman, S. L., McMasters, K. M. & Zhou, H. S. Oncolytic replication of E1b-deleted adenoviruses. Viruses 7, 5767\u20135779 (2015).","journal-title":"Viruses"},{"key":"1704_CR36","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/jnci\/djj111","volume":"98","author":"K Garber","year":"2006","unstructured":"Garber, K. China approves world\u2019s first oncolytic virus therapy for cancer treatment. J. Natl Cancer Inst. 98, 298\u2013300 (2006).","journal-title":"J. Natl Cancer Inst."},{"key":"1704_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.omto.2022.03.003","volume":"25","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response. Mol. Ther. Oncolytics 25, 31\u201342 (2022).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1704_CR38","unstructured":"Fields, B. N., Knipe, D. M. & Howley, P. M. Fields Virology (Wolters Kluwer Health\/Lippincott Williams & Wilkins, 2007)."},{"key":"1704_CR39","doi-asserted-by":"publisher","first-page":"9837","DOI":"10.1128\/JVI.78.18.9837-9841.2004","volume":"78","author":"IS Novella","year":"2004","unstructured":"Novella, I. S., Ball, L. A. & Wertz, G. W. Fitness analyses of vesicular stomatitis strains with rearranged genomes reveal replicative disadvantages. J. Virol. 78, 9837\u20139841 (2004).","journal-title":"J. Virol."},{"key":"1704_CR40","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1128\/JVI.79.7.4170-4179.2005","volume":"79","author":"DF Gaddy","year":"2005","unstructured":"Gaddy, D. F. & Lyles, D. S. Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J. Virol. 79, 4170\u20134179 (2005).","journal-title":"J. Virol."},{"key":"1704_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14128","volume":"8","author":"C Rogers","year":"2017","unstructured":"Rogers, C. et al. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic\/pyroptotic cell death. Nat. Commun. 8, 14128 (2017).","journal-title":"Nat. Commun."},{"key":"1704_CR42","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41417-022-00436-7","volume":"30","author":"K Lundstrom","year":"2023","unstructured":"Lundstrom, K. Self-replicating vehicles based on negative strand RNA viruses. Cancer Gene Ther. 30, 771\u2013784 (2023).","journal-title":"Cancer Gene Ther."},{"key":"1704_CR43","first-page":"3268","volume":"6","author":"J Cook","year":"2022","unstructured":"Cook, J. et al. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. Blood Adv. 6, 3268\u20133279 (2022).","journal-title":"Blood Adv."},{"key":"1704_CR44","doi-asserted-by":"publisher","first-page":"7306","DOI":"10.1073\/pnas.1214441110","volume":"110","author":"D Finkelshtein","year":"2013","unstructured":"Finkelshtein, D., Werman, A., Novick, D., Barak, S. & Rubinstein, M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc. Natl Acad. Sci. USA 110, 7306\u20137311 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1704_CR45","doi-asserted-by":"publisher","first-page":"6420","DOI":"10.1128\/JVI.78.12.6420-6430.2004","volume":"78","author":"SC Das","year":"2004","unstructured":"Das, S. C. & Pattnaik, A. K. Phosphorylation of vesicular stomatitis virus phosphoprotein P is indispensable for virus growth. J. Virol. 78, 6420\u20136430 (2004).","journal-title":"J. Virol."},{"key":"1704_CR46","doi-asserted-by":"publisher","first-page":"15414","DOI":"10.1073\/pnas.1110854108","volume":"108","author":"KT Beier","year":"2011","unstructured":"Beier, K. T. et al. Anterograde or retrograde transsynaptic labeling of CNS neurons with vesicular stomatitis virus vectors. Proc. Natl Acad. Sci. USA 108, 15414\u201315419 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1704_CR47","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J. C. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug Discov. 18, 689\u2013706 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1704_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0413-2","volume":"14","author":"MV Maliandi","year":"2015","unstructured":"Maliandi, M. V. et al. AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-kappaB mediated uPAR activation. Mol. Cancer 14, 146 (2015).","journal-title":"Mol. Cancer"},{"key":"1704_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02854-5","volume":"23","author":"S Mei","year":"2023","unstructured":"Mei, S., Chen, X., Wang, K. & Chen, Y. Tumor microenvironment in ovarian cancer peritoneal metastasis. Cancer Cell Int. 23, 11 (2023).","journal-title":"Cancer Cell Int."},{"key":"1704_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1634\/theoncologist.2020-0196","volume":"26","author":"T Safra","year":"2021","unstructured":"Safra, T. et al. Weekly carboplatin and paclitaxel: a retrospective comparison with the three-weekly schedule in first-line treatment of ovarian cancer. Oncologist 26, 30\u201339 (2021).","journal-title":"Oncologist"},{"key":"1704_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe2555","volume":"12","author":"A Popa","year":"2020","unstructured":"Popa, A. et al. Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. Sci. Transl. Med. 12, eabe2555 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1704_CR52","doi-asserted-by":"publisher","first-page":"898631","DOI":"10.3389\/fimmu.2022.898631","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. & Nagalo, B. M. Immunovirotherapy based on recombinant vesicular stomatitis virus: where are we?. Front. Immunol. 13, 898631 (2022).","journal-title":"Front. Immunol."},{"key":"1704_CR53","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41592-020-0889-6","volume":"17","author":"Y Su","year":"2020","unstructured":"Su, Y. et al. Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals. Nat. Methods 17, 852\u2013860 (2020).","journal-title":"Nat. Methods"},{"key":"1704_CR54","doi-asserted-by":"publisher","first-page":"e01885","DOI":"10.1128\/JVI.01885-18","volume":"93","author":"C Bressy","year":"2019","unstructured":"Bressy, C., Droby, G. N., Maldonado, B. D., Steuerwald, N. & Grdzelishvili, V. Z. Cell cycle arrest in G2\/M phase enhances replication of interferon-sensitive cytoplasmic RNA viruses via inhibition of antiviral gene expression. J. Virol. 93, e01885\u201318 (2019).","journal-title":"J. Virol."},{"key":"1704_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0744-y","volume":"18","author":"MC Bourgeois-Daigneault","year":"2016","unstructured":"Bourgeois-Daigneault, M. C. et al. Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. Breast Cancer Res. 18, 83 (2016).","journal-title":"Breast Cancer Res."},{"key":"1704_CR56","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/0092-8674(86)90779-8","volume":"45","author":"CI Bargmann","year":"1986","unstructured":"Bargmann, C. I., Hung, M. C. & Weinberg, R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649\u2013657 (1986).","journal-title":"Cell"},{"key":"1704_CR57","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/jnci\/djj413","volume":"98","author":"X Lun","year":"2006","unstructured":"Lun, X. et al. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J. Natl Cancer Inst. 98, 1546\u20131557 (2006).","journal-title":"J. Natl Cancer Inst."},{"key":"1704_CR58","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1182\/hematology.2020000171","volume":"2020","author":"ER Engel","year":"2020","unstructured":"Engel, E. R. & Walter, J. E. Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs. Hematology Am. Soc. Hematol. Educ. Program 2020, 312\u2013318 (2020).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"1704_CR59","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/40540","volume":"388","author":"RA Manz","year":"1997","unstructured":"Manz, R. A., Thiel, A. & Radbruch, A. Lifetime of plasma cells in the bone marrow. Nature 388, 133\u2013134 (1997).","journal-title":"Nature"},{"key":"1704_CR60","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ana.25701","volume":"87","author":"P Alping","year":"2020","unstructured":"Alping, P. et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann. Neurol. 87, 688\u2013699 (2020).","journal-title":"Ann. Neurol."},{"key":"1704_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s40425-019-0613-1","volume":"7","author":"W Damsky","year":"2019","unstructured":"Damsky, W. et al. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. J. Immunother. Cancer 7, 153 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1704_CR62","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/cmi.2017.35","volume":"14","author":"A Sarvaria","year":"2017","unstructured":"Sarvaria, A., Madrigal, J. A. & Saudemont, A. B cell regulation in cancer and anti-tumor immunity. Cell. Mol. Immunol. 14, 662\u2013674 (2017).","journal-title":"Cell. Mol. Immunol."},{"key":"1704_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49581-4","volume":"9","author":"Y Murakami","year":"2019","unstructured":"Murakami, Y. et al. Increased regulatory B cells are involved in immune evasion in patients with gastric cancer. Sci. Rep. 9, 13083 (2019).","journal-title":"Sci. Rep."},{"key":"1704_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16928-8","volume":"7","author":"S Hutzler","year":"2017","unstructured":"Hutzler, S. et al. Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles. Sci. Rep. 7, 16892 (2017).","journal-title":"Sci. Rep."},{"key":"1704_CR65","doi-asserted-by":"publisher","first-page":"e72162","DOI":"10.1371\/journal.pone.0072162","volume":"8","author":"MS Anglesio","year":"2013","unstructured":"Anglesio, M. S. et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS ONE 8, e72162 (2013).","journal-title":"PLoS ONE"},{"key":"1704_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41941-4","volume":"9","author":"A Hallas-Potts","year":"2019","unstructured":"Hallas-Potts, A., Dawson, J. C. & Herrington, C. S. Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas. Sci. Rep. 9, 5515 (2019).","journal-title":"Sci. Rep."},{"key":"1704_CR67","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/his.13704","volume":"73","author":"T Koopman","year":"2018","unstructured":"Koopman, T. et al. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation. Histopathology 73, 852\u2013863 (2018).","journal-title":"Histopathology"},{"key":"1704_CR68","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.3390\/jcm11236963","volume":"11","author":"MK Yeo","year":"2022","unstructured":"Yeo, M. K., Kim, S., Yoo, H. J., Suh, K. S. & Kim, K. H. HER2 expression in peritoneal dissemination of high-grade serous ovarian carcinoma: a comparative study of immunohistochemical reactivity using four HER2 antibodies. J. Clin. Med. 11, 6963 (2022).","journal-title":"J. Clin. Med."},{"key":"1704_CR69","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-022-01828-7","volume":"83","author":"NAD Guchelaar","year":"2023","unstructured":"Guchelaar, N. A. D. et al. Intraperitoneal chemotherapy for unresectable peritoneal surface malignancies. Drugs 83, 159\u2013180 (2023).","journal-title":"Drugs"},{"key":"1704_CR70","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.3390\/biomedicines10092216","volume":"10","author":"N Deshet-Unger","year":"2022","unstructured":"Deshet-Unger, N. et al. Comparing intraperitoneal and intravenous personalized ErbB2CAR-T for the treatment of epithelial ovarian cancer. Biomedicines 10, 2216 (2022).","journal-title":"Biomedicines"},{"key":"1704_CR71","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/s10637-019-00857-6","volume":"38","author":"R van der Noll","year":"2020","unstructured":"van der Noll, R. et al. Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Invest. New Drugs 38, 1096\u20131107 (2020).","journal-title":"Invest. New Drugs"},{"key":"1704_CR72","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.2147\/IJN.S362263","volume":"17","author":"H Tang","year":"2022","unstructured":"Tang, H. et al. Estrone-conjugated PEGylated liposome Co-loaded paclitaxel and carboplatin improve anti-tumor efficacy in ovarian cancer and reduce acute toxicity of chemo-drugs. Int. J. Nanomedicine 17, 3013\u20133041 (2022).","journal-title":"Int. J. Nanomedicine"},{"key":"1704_CR73","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West, H. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924\u2013937 (2019).","journal-title":"Lancet Oncol."},{"key":"1704_CR74","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.19.01009","volume":"37","author":"KS Tewari","year":"2019","unstructured":"Tewari, K. S. et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J. Clin. Oncol. 37, 2317\u20132328 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1704_CR75","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","volume":"8","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti, B. et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 8, 1160\u20131168 (2022).","journal-title":"JAMA Oncol."},{"key":"1704_CR76","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.3390\/ijms22126532","volume":"22","author":"S Morand","year":"2021","unstructured":"Morand, S., Devanaboyina, M., Staats, H., Stanbery, L. & Nemunaitis, J. Ovarian cancer immunotherapy and personalized medicine. Int. J. Mol. Sci. 22, 6532 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1704_CR77","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha, D. et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 10, 1808\u20131825 (2020).","journal-title":"Cancer Discov."},{"key":"1704_CR78","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s00432-022-04412-4","volume":"149","author":"MS Kim","year":"2023","unstructured":"Kim, M. S. & Prasad, V. Pembrolizumab for all. J. Cancer Res. Clin. Oncol. 149, 1357\u20131360 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1704_CR79","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/mt.2008.212","volume":"16","author":"T Kottke","year":"2008","unstructured":"Kottke, T. et al. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol. Ther. 16, 1910\u20131918 (2008).","journal-title":"Mol. Ther."},{"key":"1704_CR80","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-07-1510","volume":"14","author":"J Qiao","year":"2008","unstructured":"Qiao, J. et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin. Cancer Res. 14, 259\u2013269 (2008).","journal-title":"Clin. Cancer Res."},{"key":"1704_CR81","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.3390\/jcm11102807","volume":"11","author":"E Robak","year":"2022","unstructured":"Robak, E. & Robak, T. Bruton\u2019s kinase inhibitors for the treatment of immunological diseases: current status and perspectives. J. Clin. Med. 11, 2807 (2022).","journal-title":"J. Clin. Med."},{"key":"1704_CR82","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3390\/molecules28052400","volume":"28","author":"D Rozkiewicz","year":"2023","unstructured":"Rozkiewicz, D., Hermanowicz, J. M., Kwiatkowska, I., Krupa, A. & Pawlak, D. Bruton\u2019s tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials. Molecules 28, 2400 (2023).","journal-title":"Molecules"},{"key":"1704_CR83","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/hum.2009.111","volume":"21","author":"N Jenks","year":"2010","unstructured":"Jenks, N. et al. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum. Gene Ther. 21, 451\u2013462 (2010).","journal-title":"Hum. Gene Ther."},{"key":"1704_CR84","doi-asserted-by":"publisher","first-page":"8843","DOI":"10.1128\/JVI.77.16.8843-8856.2003","volume":"77","author":"M Obuchi","year":"2003","unstructured":"Obuchi, M., Fernandez, M. & Barber, G. N. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77, 8843\u20138856 (2003).","journal-title":"J. Virol."},{"key":"1704_CR85","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.virol.2020.06.013","volume":"548","author":"KA Marquis","year":"2020","unstructured":"Marquis, K. A., Becker, R. L., Weiss, A. N., Morris, M. C. & Ferran, M. C. The VSV matrix protein inhibits NF-\u03baB and the interferon response independently in mouse L929 cells. Virology 548, 117\u2013123 (2020).","journal-title":"Virology"},{"key":"1704_CR86","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.virol.2012.11.014","volume":"436","author":"M Moerdyk-Schauwecker","year":"2013","unstructured":"Moerdyk-Schauwecker, M. et al. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology 436, 221\u2013234 (2013).","journal-title":"Virology"},{"key":"1704_CR87","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.omto.2020.05.004","volume":"17","author":"RS Bayne","year":"2020","unstructured":"Bayne, R. S. et al. MAP3K7 and CHD1 are novel mediators of resistance to oncolytic vesicular stomatitis virus in prostate cancer cells. Mol. Ther. Oncolytics 17, 496\u2013507 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1704_CR88","doi-asserted-by":"publisher","first-page":"200826","DOI":"10.1016\/j.omton.2024.200826","volume":"32","author":"K Geoffroy","year":"2024","unstructured":"Geoffroy, K., Mullins-Dansereau, V., Leclerc-Desaulniers, K., Viens, M. & Bourgeois-Daigneault, M.-C. Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer. Mol. Ther. Oncol. 32, 200826 (2024).","journal-title":"Mol. Ther. Oncol."},{"key":"1704_CR89","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.3390\/cancers15205009","volume":"15","author":"I Marrocco","year":"2023","unstructured":"Marrocco, I. & Yarden, Y. Resistance of lung cancer to EGFR-specific kinase inhibitors: activation of bypass pathways and endogenous mutators. Cancers 15, 5009 (2023).","journal-title":"Cancers"},{"key":"1704_CR90","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4161\/mabs.1.3.8292","volume":"1","author":"L Reslan","year":"2009","unstructured":"Reslan, L., Dalle, S. & Dumontet, C. Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs 1, 222\u2013229 (2009).","journal-title":"MAbs"},{"key":"1704_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02334-6","volume":"24","author":"Y Lu","year":"2025","unstructured":"Lu, Y. & Zhao, F. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Mol. Cancer 24, 126 (2025).","journal-title":"Mol. Cancer"},{"key":"1704_CR92","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41573-022-00415-5","volume":"21","author":"G Petroni","year":"2022","unstructured":"Petroni, G., Buque, A., Coussens, L. M. & Galluzzi, L. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat. Rev. Drug Discov. 21, 440\u2013462 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1704_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2015.12","volume":"2","author":"C Ayala Breton","year":"2015","unstructured":"Ayala Breton, C. et al. Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity. Mol. Ther. Oncolytics 2, 15012 (2015).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1704_CR94","doi-asserted-by":"publisher","first-page":"e0037223","DOI":"10.1128\/jvi.00372-23","volume":"97","author":"Y Gao","year":"2023","unstructured":"Gao, Y. & Bergman, I. Vesicular stomatitis virus (VSV) G glycoprotein can be modified to create a Her2\/Neu-targeted VSV that eliminates large implanted mammary tumors. J. Virol. 97, e0037223 (2023).","journal-title":"J. Virol."},{"key":"1704_CR95","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1016\/j.cell.2022.11.016","volume":"185","author":"B Yu","year":"2022","unstructured":"Yu, B. et al. Engineered cell entry links receptor biology with single-cell genomics. Cell 185, 4904\u20134920.e22 (2022).","journal-title":"Cell"},{"key":"1704_CR96","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.3390\/cells10113177","volume":"10","author":"S Fischer","year":"2021","unstructured":"Fischer, S., Proschmann, U., Akg\u00fcn, K. & Ziemssen, T. Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects. Cells 10, 3177 (2021).","journal-title":"Cells"},{"key":"1704_CR97","doi-asserted-by":"publisher","first-page":"e70074","DOI":"10.1002\/cpz1.70074","volume":"4","author":"F Costacurta","year":"2024","unstructured":"Costacurta, F., Rauch, S., von Laer, D. & Heilmann, E. Using vesicular stomatitis virus as a platform for directed protease evolution. Curr. Protoc. 4, e70074 (2024).","journal-title":"Curr. Protoc."},{"key":"1704_CR98","doi-asserted-by":"publisher","unstructured":"Zou, X. & Lin, M. \u201cRewiring oncogenic signaling to precision ablation of metastatic cancer\u201d cell and animal images. Zenodo https:\/\/doi.org\/10.5281\/zenodo.19296313 (2026).","DOI":"10.5281\/zenodo.19296313"}],"updated-by":[{"DOI":"10.1038\/s41551-026-01753-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000}}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01704-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01704-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01704-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:03:09Z","timestamp":1783494189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01704-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":98,"alternative-id":["1704"],"URL":"https:\/\/doi.org\/10.1038\/s41551-026-01704-9","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41551-026-01753-0","URL":"https:\/\/doi.org\/10.1038\/s41551-026-01753-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.Z. and M.Z.L. are inventors on a patent application describing the viral constructs in this study. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}